Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Epithelial Neoplasms

imatinib mesylate has been researched along with Epithelial Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Klein-Szanto, AJ; Lee, RB; Miner, Z; Schilder, RJ; Senterman, MK; Shaw, TJ; Sill, MW; Vanderhyden, BC1
Aghajanian, C; Hensley, ML; Iasonos, A; Juretzka, M; Konner, J; Leitao, M; Park, K; Sabbatini, P; Soslow, R; Tew, W1
Andreopoulou, E; Blank, S; Borgato, L; Boyd, L; Curtin, J; Levinson, B; Muggia, F; Pothuri, B; Safra, T; Tiersten, A1
Buonerba, C; Ceribelli, A; Conti, S; Damiano, V; De Placido, S; Di Lorenzo, G; Evoli, A; Federico, P; Lalle, M; Marino, M; Matano, E; Merola, G; Milella, M; Palmieri, G; Petillo, L; Sioletic, S1

Trials

4 trial(s) available for imatinib mesylate and Epithelial Neoplasms

ArticleYear
Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Probability; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome

2008
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.
    European journal of gynaecological oncology, 2008, Volume: 29, Issue:6

    Topics: Administration, Oral; Adult; Aged; Benzamides; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2008
Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.
    Anticancer research, 2010, Volume: 30, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy

2010
Imatinib mesylate in thymic epithelial malignancies.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Benzamides; Diarrhea; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Migraine Disorders; Mutation; Neoplasms, Glandular and Epithelial; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Thymus Neoplasms; Treatment Outcome

2012